KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
8.96
-0.09 (-0.99%)
Nov 20, 2024, 4:00 PM EST - Market closed
KalVista Pharmaceuticals Employees
KalVista Pharmaceuticals had 150 employees as of April 30, 2024. The number of employees increased by 32 or 27.12% compared to the previous year.
Employees
150
Change (1Y)
32
Growth (1Y)
27.12%
Revenue / Employee
n/a
Profits / Employee
-$945,133
Market Cap
387.21M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
DocGo | 4,164 |
Sonida Senior Living | 3,955 |
Canopy Growth | 1,029 |
Revance Therapeutics | 597 |
Sangamo Therapeutics | 405 |
Prime Medicine | 234 |
Rigel Pharmaceuticals | 147 |
Larimar Therapeutics | 42 |
KALV News
- 9 days ago - KalVista Pharmaceuticals to Present at Upcoming Investor Conferences - Business Wire
- 16 days ago - KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 17 days ago - KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million - Business Wire
- 17 days ago - KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust - Business Wire
- 24 days ago - KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology - Business Wire
- 4 weeks ago - KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) - Business Wire
- 6 weeks ago - KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum - Business Wire
- 7 weeks ago - KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema - Business Wire